FDA Gives Accelerated Approval to Sevabertinib in HER2+ NSCLC

The FDA granted accelerated approval to sevabertinib for frontline treatment of metastatic non-squamous NSCLC with HER2 TKD activating mutations based on promising trial results.

This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it.